专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20230074198A1 Viral vector particle based on AA V2 for gene therapy 有权
公开(公告)号：US20230074198A1
公开(公告)日：2023-03-09
申请号：US17800338
申请日：2021-02-22
申请人： Medizinische Hochschule Hannover
发明人： Thomas Thum , Hildegard Büning , Laura Rode , Christian Bär
IPC分类号： C12N15/86
摘要： The invention provides a viral vector particle based on AAV2, which in its capsid protein (CAP) contains an inserted amino acid section which confers tropism for cardiomyocytes.

2. 发明申请

US20220357324A1 TCR-INDEPENDENT MOLECULAR IDENTIFICATION OF MUTATION-RELATED AND TUMOR-SPECIFIC T CELLS 有权
公开(公告)号：US20220357324A1
公开(公告)日：2022-11-10
申请号：US17754452
申请日：2020-10-15
申请人： MEDIZINISCHE HOCHSCHULE HANNOVER
发明人： Norman WOLLER
IPC分类号： G01N33/569 , G01N33/574
摘要： The present invention relates to the field of tumor immunology. It provides a method for identifying mutation-related human CD8+ T cells, in particular, tumor-specific T cells of a human subject, comprising analyzing CD8+ T cells of the subject by analysing the expression of at least one marker selected from a first group consisting of CD82, CD194, CD244, CD28, CD62L and CD55, and preferably, a marker selected from a second group comprising CD11a or CD18 or CD43. A preferred marker for mutation-related CD8+ T cells is CD82, which may be analysed in combination, e.g., with CD11a. Without the need to identify any epitope to which T cells reacts, this method can advantageously be used to isolate the entire individual pool of mutation-related T cells, and, optionally, to identify the sequence of a mutation-related TCR, which allows for generation of transgenic T cells expressing the TCR. Compositions substantially comprising tumor-specific CD82hiCD8+ T cells and/or CD194hi, CD244−, CD28+, CD62L+ and/or CD55+ CD82hi CD8+ T cells can be used for treatment of a cancer patient, e.g., by adoptive T cell transfer. The method of the invention can also be used for diagnostic purposes to identify human mutation-related T cells or diagnosing a tumor disease or for testing responses of a cancer patient to an immune stimulatory therapy, preferably, a therapy with a checkpoint inhibitor.

3. 发明授权

US11471617B2 Nebultzation of immunoglobulin 有权
公开(公告)号：US11471617B2
公开(公告)日：2022-10-18
申请号：US15300820
申请日：2015-04-02
申请人： CSL BEHRING AG , PARI PHARMA GMBH , MEDIZINISCHE HOCHSCHULE HANNOVER
发明人： Cédric Pierre Vonarburg , Karin Steinfuehrer , Ulrich Baumann
IPC分类号： A61M11/00 , A61K9/00 , A61K39/395 , C07K16/10 , C07K16/12 , B05B17/00 , A61M15/00 , C07K16/00 , A61K39/00
摘要： The invention relates to methods for generating an aerosol by nebulization of a composition comprising polyclonal immunoglobulin (Ig). The selection of an efficient membrane nebulizer and a composition optimized for nebulization with such membrane nebulizer results in a particularly efficient method of generating an aerosol for administration of Ig to the respiratory tract.

4. 发明申请

US20220315924A1 LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY 有权
公开(公告)号：US20220315924A1
公开(公告)日：2022-10-06
申请号：US17658957
申请日：2022-04-12
申请人： Medizinische Hochschule Hannover
发明人： Thomas THUM , Kumarswamy REGALLA , Janika VIERECK
IPC分类号： C12N15/113 , A61K48/00 , A61P9/00 , C12Q1/6883
摘要： The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.

5. 发明申请

US20220265799A1 ANALYTICAL METHOD AND IMMUNOLOGICAL TREATMENT FOR BLADDER CANCER 有权
公开(公告)号：US20220265799A1
公开(公告)日：2022-08-25
申请号：US17631598
申请日：2020-07-30
申请人： Medizinische Hochschule Hannover
发明人： Falk Büttner , Charlotte Rossdam , Rita Gerardy-Schahn , Astrid Oberbeck , Hossein Tezval
IPC分类号： A61K39/00 , G01N33/574
摘要： The invention provides an analytical method for detecting bladder cancer by analysing a urine sample for presence of a glycan tumour antigen, the presence of which has been identified to indicate bladder cancer. The analytical method has the advantage that the tumour antigen can be analysed in a urine sample and has a high accuracy for indicating presence of cancer in the urinary tract, especially bladder cancer, e.g. the method has a low rate of false positive results.

6. 发明授权

US11413307B2 Induced dendritic cells and uses thereof 有权
公开(公告)号：US11413307B2
公开(公告)日：2022-08-16
申请号：US16395627
申请日：2019-04-26
申请人： MEDIZINISCHE HOCHSCHULE HANNOVER
发明人： Renata Stripecke , Gustavo Salguero-Lopez , Anusara Daenthanasanmak , Arnold Ganser
IPC分类号： A61K35/15 , C12N5/0784 , A01K67/027 , A61K49/00 , A61K35/12 , A61K39/00
摘要： The present invention relates to cells engineered to express at least one cytokine and at least one antigen which induces the self differentiation of dendritic cell (DC) progenitor cells into functional antigen-presenting induced DC (iDC). Moreover, therapeutic uses of said iDC for regenerating the immune system after transplantation of hematopoietic stem cells are disclosed. Said iDC are also useful for generating mice with a functional endogenously regenerated humanized immune system producing antigen-specific T and B cell responses which can be used as animal models for the study of the human adaptive immune responses.

7. 发明申请

US20220211906A1 METHOD FOR COATING A MEDICAL DEVICE AND COATED MEDICAL DEVICE 有权
公开(公告)号：US20220211906A1
公开(公告)日：2022-07-07
申请号：US17610611
申请日：2020-05-20
申请人： MEDIZINISCHE HOCHSCHULE HANNOVER
发明人： Meike STIESCH , Sascha Nico STUMPP , Michael EISENBURGER , Muhammad Imran RAHIM
IPC分类号： A61L27/34 , A61L27/36 , A61L27/54
摘要： The present invention relates in a first aspect to a method for coating a medical device suitable for implantation into an individual or for application on skin or mucosal tissue of an individual. Said method comprises the steps of applying to at least a portion of the surface of said device a coating layer whereby said coating layer comprises commensal microorganisms, like commensal bacteria, to form a biofilm on the at least portion of the surface of said medical device, further comprising the step of drying the biofilm coated on the surface of said medical device whereby the commensal microorganisms are eventually killed in case they were not applied as killed microorganisms in the step above, for obtaining a medical device having at least a portion of its surface coated with non-living commensal microorganisms In a further aspect, the coated medical devices obtainable by the method according to the present invention are provided. The coated medical devices according to the present invention are particularly useful in applications being mucosal tissue or a skin of an individual, like for use as an implant for dental use in the oral cavity. Finally, the present invention relates to the use of commensal bacteria like Streptococcus oralis for coating a medical device suitable for use as an implant into an individual or for application on skin or mucosal tissue of an individual.

8. 发明授权

US11371043B2 LncRNAs for therapy and diagnosis of cardiac hypertrophy 有权
公开(公告)号：US11371043B2
公开(公告)日：2022-06-28
申请号：US16017375
申请日：2018-06-25
申请人： Medizinische Hochschule Hannover
发明人： Thomas Thum , Kumarswamy Regalla , Janika Viereck
IPC分类号： C12N15/113 , A61P9/00 , A61K48/00 , C12Q1/6883
摘要： The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii)a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28. The present invention also relates to a compound (i) promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 12, 8 to 11 and 13; and/or (ii) inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 1 to 7, 27 and 28 for use in treating or preventing cardiac hypertrophy.

9. 发明申请

US20220136006A1 RECOMBINANT VECTORS SUITABLE FOR THE TREATMENT OF IPEX SYNDROME 有权
公开(公告)号：US20220136006A1
公开(公告)日：2022-05-05
申请号：US17428401
申请日：2020-02-04
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , FONDATION IMAGINE , UNIVERSITÉ DE PARIS , UNIVERSITÉ D'EVRY-VAL-D'ESSONE , MEDIZINISCHE HOCHSCHULE HANNOVER (MHH)
发明人： Isabelle ANDRE , Emmanuelle SIX , Florence BELLIER , Marianne DELVILLE , Mariana CAVAZZANA , Mario AMENDOLA , Axel SCHAMBACH
IPC分类号： C12N15/86 , A61K35/17
摘要： IPEX (Immune dysregulation Polyendocinopathy X linked) syndrome is a primary immunodeficience caused by mutations in the gene encoding the transcription factor forkhead box P3 (FOXP3), which leads to the loss of function of thymus-derived CD4+CD25+ regulatory T (tTreg) cells. Preclinical and clinical studies suggest that T cell gene therapy approaches designed to selectively restore the repertoire of Treg cells by transfer of wild type FOXP3 gene is a promising potential cure for IPEX. However, there is still a need for a vector that can be used efficiently for the preparation of said Treg cells. The inventors thus compared 6 different lentiviral constructs according to 4 criteria (vector titers, level of transduction of human CD4+ T cells, level of expression of FOXP3 and ΔLNGFR genes, degree of correlation between both expression) and selected one construct comprising a bidirectional EFS-PGK promoter that showed remarkable efficiency.

10. 发明申请

US20220023257A1 TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES 有权
公开(公告)号：US20220023257A1
公开(公告)日：2022-01-27
申请号：US17279777
申请日：2019-09-30
申请人： Medizinische Hochschule Hannover (MHH) , Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (DZNE)
发明人： Evgeni Ponimaskin , Kian-Fritz Roehrs , Malte Butzlaff , Josephine Labus , Alexander Dityatev , Hristo Varbanov , Jia Shaobo , Sun Weilun
IPC分类号： A61K31/40 , A61K31/454 , A61K31/55 , A61K31/5513 , A61K31/496 , A61K31/495 , A61K31/166 , A61P25/28
摘要： The present invention relates to a 5-HT7 receptor antagonist for use in preventing or treating a tauopathy. Further, the present invention also relates to a pharmaceutical composition for use in preventing or treating a tauopathy comprising the 5-HT7 receptor antagonist as mentioned above.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式